Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316

MT Newswires Live
2024-10-11

Acrivon Therapeutics (ACRV) said Friday that the first patient has been dosed in its phase 1 clinical trial evaluating ACR-2316, which is being developed to treat patients with solid tumors.

The company said the trial will determine the maximal tolerated dose and recommended phase 2 monotherapy dose, characterization of the pharmacokinetic profile and preliminary evaluation of anti-tumor activity.

Price: 7.00, Change: +0.02, Percent Change: +0.29

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10